FMP
Qualigen Therapeutics, Inc.
QLGN
NASDAQ
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
3.1 USD
0.04 (1.29%)
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
607.64M
892.25M
1.06B
1.31B
1.43B
1.78B
2.22B
2.76B
3.44B
4.29B
29.18M
-54.96M
-9.98M
299.08M
320.56M
153.13M
190.78M
237.68M
296.12M
368.92M
-3.19M
-13.06M
-23.82M
-7.34M
-14.92M
-20.82M
-25.94M
-32.31M
-40.26M
-50.16M
25.98M
-68.02M
-33.8M
291.74M
305.64M
132.31M
164.84M
205.37M
255.86M
318.76M
-
-
-
-
-
-
-
-
-
-
-